Three lots of buprenorphine hydrochloride, used for pain management, and two lots of labetalol hydrochloride, indicated for blood pressure control in severe hypertension cases, were recalled. The injectable drugs might have incomplete crimp seals, the FDA said May 21.
Pfizer has received one customer complaint about a leaking unit, and there are no reports of adverse events.
“Wholesalers and hospitals with an existing inventory of any of the lots which are being recalled should discontinue use, stop distribution and quarantine the product immediately,” the FDA said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.